Discrepancies in Drug Susceptibility Test for Tuberculosis Patients Resulted from the Mixed Infection and the Testing System

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Mei, Zaoxian ^a,b   Sun, Zhaogang ^c   Bai, Dapeng ^a,b   Xu, Yuhui ^c   Li, Zhiling ^a,b   Huang, Hairong ^c   Li, Chuanyou ^c   Xu, Shaofa ^c   Li, Li ^a,b  

^a Tianjin Haihe Hospital   (China)

^b Tianjin Respiratory Disease Research Institute   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; BACTERIAL PROTEIN; CATALASE; ISONIAZID; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

AHPC GENE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BROTH DILUTION; CODON; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; INHA GENE; KATG GENE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MOLECULAR TYPING; NONHUMAN; OPEN READING FRAME; REGULATORY SEQUENCE; TUBERCULOSIS; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PATHOLOGY;

MYCOBACTERIUM TUBERCULOSIS;

BACTERIAL PROTEINS; CATALASE; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84929649103     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/651980     Document Type: Article

References (35)

1. J. G. Pasipanodya, S. Srivastava, and T. Gumbo, "Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy," Clinical Infectious Diseases, vol. 55, no. 2, pp. 169-177, 2012.
2. P. T. Kent and G. P. Kubica, Public Health Mycobacteriology. A Guide for Level III Laboratory, Centers for Diseases Control, Atlanta, Ga, USA, 1985.
3. S. B. Walters and B. A. Hanna, "Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method," Journal of Clinical Microbiology, vol. 34, no. 6, pp. 1565-1567, 1996.
4. A. Wanger and K. Mills, "Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest," Journal of Clinical Microbiology, vol. 34, no. 7, pp. 1672-1676, 1996.
5. L. A. Collins and S. G. Franzblau, "Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium," Antimicrobial Agents and Chemotherapy, vol. 41, no. 5, pp. 1004-1009, 1997.
6. C. Piersimoni, "TB control strategies: present and future in diagnostic methods: what the clinician can ask to the lab,"Monaldi Archives for Chest Disease, vol. 57, no. 5-6, pp. 306-310, 2002.
7. G. L. Woods, G. Fish, M. Plaunt, and T. Murphy, "Clinical evaluation of Difco ESP culture system II for growth and detection of mycobacteria," Journal of Clinical Microbiology, vol. 35, no.1, pp.121-124, 1997.
8. R. A. Adegbola, P. Hill, I. Baldeh et al., "Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia," International Journal of Tuberculosis and Lung Disease, vol. 7, no. 4, pp. 390-393, 2003.
9. C. M. S. Giampaglia, M. C. Martins, G. B. De Oliveira Vieira et al., "Multicentre evaluation of an automated BACTEC 960 system for susceptibility testing of Mycobacterium tuberculosis," International Journal of Tuberculosis and Lung Disease, vol. 11, no. 9, pp. 986-991, 2007.
10. L. Heifets and G. A. Cangelosi, "Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century," International Journal of Tuberculosis and Lung Disease, vol. 3, no. 7, pp. 564-581, 1999.
11. C. Piersimoni, A. Olivieri, L. Benacchio, and C. Scarparo, "Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems," Journal of Clinical Microbiology, vol. 44, no. 1, pp. 20-28, 2006.
12. Chinese Anti-Tuberculosis Association, Protocols for Tuberculosis Diagnosis in Laboratory, Chinese Educational and Cultural Publisher, Beijing, China, 1st edition, 2006.
13. J.-C. Palomino, A. Martin, M. Camacho, H. Guerra, J. Swings, and F. Portaels, "Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis," Antimicrobial Agents and Chemotherapy, vol. 46, no. 8, pp. 2720-2722, 2002.
14. N. Siddiqi, M. Shamim, S. Hussain et al., "Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India," Antimicrobial Agents and Chemotherapy, vol. 46, no. 2, pp. 443-450, 2002.
15. M. Y. Lipin, V. N. Stepanshina, I. G. Shemyakin, and T. M. Shinnick, "Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia," Clinical Microbiology and Infection, vol. 13, no. 6, pp. 620-626, 2007.
16. Z. Sun, J. Zhang, X. Zhang, S. Wang, Y. Zhang, and C. Li, "Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates," International Journal of Antimicrobial Agents, vol. 31, no. 2, pp. 115-121, 2008.
17. J. Kamerbeek, L. Schouls, A. Kolk et al., "Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology," Journal of Clinical Microbiology, vol. 35, no. 4, pp. 907-914, 1997.
18. Z. H. Helal, M. S. E.-D. Ashour, S. A. Eissa et al., "Unexpectedly high proportion of ancestral manu genotype Mycobacterium tuberculosis strains cultured from tuberculosis patients in Egypt," Journal of Clinical Microbiology, vol. 47, no. 9, pp. 2794-2801, 2009.
19. P. Supply, E. Mazars, S. Lesjean, V. Vincent, B. Gicquel, and C. Locht, "Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome," Molecular Microbiology, vol. 36, no. 3, pp. 762-771, 2000.
20. M. B. Boniotti, M. Goria, D. Loda et al., "Molecular typing of Mycobacterium bovis strains isolated in Italy from 2000 to 2006 and evaluation of variable-number tandem repeats for geographically optimized genotyping," Journal of Clinical Microbiology, vol. 47, no. 3, pp. 636-644, 2009.
21. W. H. Benjamin Jr., K. B. Waites, A. Beverly et al., "Comparison of the MB/BacT system with a revised antibiotic supplement kit to the BACTEC 460 system for detection of mycobacteria in clinical specimens," Journal of Clinical Microbiology, vol. 36, no. 11, pp. 3234-3238, 1998.
22. World Health Organisation, The Use of Liquid Medium for Culture and DST in Middle- and Low-Income Countries, 2007, http://www.who.int/tb/dots/laboratory/policy/en/index3.htm.
23. W. W. Yew, S. C. W. Tong, K. S. Lui, S. K. F. Leung, C. H. Chau, and E. P. Wang, "Comparison of MB/BacT system and agar proportion method in drug susceptibility testing of Mycobacterium tuberculosis," Diagnostic Microbiology and Infectious Disease, vol. 39, no. 4, pp. 229-232, 2001.
24. Y. Balabanova, F. Drobniewski, V. Nikolayevskyy et al., "An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia," PLoS ONE, vol. 4, no. 9, Article ID e7129, 2009.
25. L. Lawson, N. Emenyonu, S. T. Abdurrahman et al., "Comparison of Mycobacterium tuberculosis drug susceptibility using solid and liquid culture in Nigeria," BMC Research Notes, vol. 6, no. 1, article 215, 2013.
26. S. J. Kim, "Drug-susceptibility testing in tuberculosis: methods and reliability of results," European Respiratory Journal, vol. 25, no. 3, pp. 564-569, 2005.
27. World Health Organization, "Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs," 2008, http://www.who.int/tb/features-archive/xdr-mdr-policy-guidance.
28. I. C. Shamputa, L. Jugheli, N. Sadradze et al., "Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia,"Respiratory Research, vol. 7, article 99, 2006.
29. I. C. Shamputa, L. Rigouts, L. A. Eyongeta et al., "Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients," Journal of Clinical Microbiology, vol. 42, no.12, pp. 5528-5536, 2004.
30. M. N. T. Huyen, T. N. Buu, E. Tiemersma et al., "Tuberculosis relapse in vietnam is significantly associated with Mycobacterium tuberculosis Beijing genotype infections," The Journal of Infectious Diseases, vol. 207, no. 10, pp. 1516-1524, 2013.
31. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis, "Beijing/W genotype Mycobacterium tuberculosis and drug resistance," Emerging Infectious Diseases, vol. 12, no. 5, pp. 736-743, 2006.
32. B. C. De Jong, P. C. Hill, A. Aiken et al., "Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in the Gambia," Journal of Infectious Diseases, vol. 198, no. 7, pp. 1037-1043, 2008.
33. M. Hanekom, G. D. van der Spuy, E. Streicher et al., "A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease," Journal of Clinical Microbiology, vol. 45, no. 5, pp. 1483-1490, 2007.
34. Y. Kong, M. D. Cave, L. Zhang et al., "Association between Mycobacterium tuberculosis Beijing/W lineage strain infection and extrathoracic tuberculosis: Insights from epidemiologic and clinical characterization of the three principal genetic groups of M. tuberculosis clinical isolates," Journal of Clinical Microbiology, vol. 45, no. 2, pp. 409-414, 2007.
35. Y. Pang, Y. Zhou, B. Zhao et al., "Spoligotyping and drug resistance analysis of Mycobacterium Tuberculosis strains from national survey in China," PLoS ONE, vol. 7, no. 3, Article ID e32976, 2012.